J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Aura bids to join the bladder cancer crowd
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
